Heart Matters

For patients with diabetes, effective care requires more than just lowering A1C. Dr. Scott Isaacs joins us to discuss the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. He’s the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.

The 2025 American College of Cardiology/American Heart Association Guideline for the Management of Patients With Acute Coronary Syndromes (ACS) reflects more than a decade of new evidence, but what will actually change at the bedside? Tune in to find out as Dr. Sunil Rao, Chair of the Joint Committee on Clinical Practice Guidelines, discusses the recommendations poised to have the greatest clinical impact and practical considerations for implementing them across the continuum of ACS care. Dr. Rao is a Professor of Medicine at the NYU Grossman School of Medicine and the Director of Interventional Cardiology at NYU Langone Health.

Even with advances in noninvasive imaging, diagnosing ATTR-CM isn’t always straightforward. That's why Dr. Sumeet Mitter joins us to discuss how we can address key challenges in diagnosis and navigate the path to treatment. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.

Because transthyretin amyloid cardiomyopathy (ATTR-CM) is a systemic disease, effective ATTR-CM management requires expertise beyond cardiology. Dr. Sumeet Mitter joins us to discuss the roles of neurology, hematology-oncology, genetic counseling, and nephrology in caring for these patients. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.

As advances in RNA silencers, gene-editing technologies, and immunotherapy reshape the ATTR-CM landscape, it's important to stay informed and build confidence navigating this increasingly complex field. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, shares practical advice about navigating the nuances of this rare disease.

The future of ATTR-CM care may extend beyond slowing disease progression to detecting it sooner—and potentially reversing its effects. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, explores emerging innovations that could open the door to earlier intervention, combination therapy, and even one-time treatment strategies.

The 2026 American College of Cardiology/American Heart Association Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults introduces a new clinical categorization framework to help evaluate risk and determine the appropriate care setting and treatment for patients with acute pulmonary embolism. Review key updates as Dr. Mary Leuchars sits down with Dr. Mark Creager, chair of the guideline writing committee. He's also a Professor of Medicine and Professor of Surgery at the Geisel School of Medicine at Dartmouth.

With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferences, and the treatment most likely to help patients achieve their LDL goals. Dr. Navar is an Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, and she served on the Guideline Writing Committee.

What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.

How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.